The SURPASS-CVOT trial finds tirzepatide noninferior but not superior to dulaglutide for major cardiovascular events in type 2 diabetes, confirming both incretin therapies are cardioprotective. PICO summary and commentary.
Browsing: Cardiovascular
Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
A prespecified SELECT analysis finds semaglutide’s cardiovascular benefit is largely independent of weight loss, with only a third mediated by waist reduction. PICO summary and commentary.
An 8-week RCT finds a hibiscus-inulin shot produces small reductions in lipid-glucose indices in overweight adults, but the authors stress these reflect analytical responsiveness, not proven clinical benefit. PICO summary and commentary.
The FIVE-STAR mechanistic trial finds finerenone does not change arterial stiffness but reduces albuminuria in diabetic kidney disease, pointing to an intraglomerular-pressure mechanism. PICO summary and commentary.
A TALOS-AMI post hoc analysis finds switching from ticagrelor to clopidogrel a month after MI is consistent across diabetes status, though within-diabetes bleeding and ischemic differences were not significant. PICO summary and commentary.
A small biomarker RCT finds empagliflozin reduces the renal tubular marker KIM-1 in diabetic heart failure with preserved ejection fraction, with no effect on other biomarkers. PICO summary and commentary.
An ASCOT analysis finds high blood pressure variability is strongly linked to worse cardiovascular and renal outcomes in diabetes, with amlodipine-based therapy reducing events partly via lower variability. PICO summary and commentary.
Summary: In adults (n=117) with coronary artery stenosis located proximal to a myocardial bridge requiring percutaneous coronary intervention, IVUS-guided stent…
An RCT finds an interdisciplinary care model with family empowerment improves blood pressure, glucose, and psychosocial outcomes in comorbid hypertension and diabetes. PICO summary and commentary.
An RCT finds intraoperative dexmedetomidine reduces glucose variability, insulin requirements, and CRP in diabetic off-pump CABG patients, though endpoints are surrogate. PICO summary and commentary.